Kotak has initiated coverage on Ranbaxy with a BUY rating in view of the company’s strong product pipeline, increased contribution of the branded generic business and acquisitions, growth from domestic and semi-regulated markets.
Ranbaxy’s Para-IV pipeline comprises around 18 first-to-file products representing a market size of ~ US$26 bn valued at innovator prices. In the next two years, the company is expected to benefit from the launch of complex injectables in the area of Penems and Limuses, which has a market potential of over US$3 bn.